NCT00361088View on ClinicalTrials.gov

A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Multiple Myeloma
Interventions
DRUG

PS-341

Phase I and II: 1.3mg/m2 iv days 1,4,8,11

DRUG

R11577

"Phase I: 100mg po BID days 1014 for Cohort 1, 200mg po BID days 1014 for Cohort 2, 300mg po BID days 1014 for Cohort 3.~Phase II: Maximum Tolerated Dose (MTD)"

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER